Today: 25 June 2026

Rivian Stock (RIVN) Today: Price Targets Raised, Battery Bug Emerges and Big Holders Trim Stakes – November 17, 2025

Rivian Stock (RIVN) Today: Price Targets Raised, Battery Bug Emerges and Big Holders Trim Stakes – November 17, 2025

Rivian shares traded near $15.06 early afternoon November 17, down 0.3% after a surge of over 30% post-Q3 earnings. The company reported its first positive gross profit, while Stifel and Tigress Financial raised price targets. Headlines flagged a battery calibration bug in R1 models, and filings showed major investors and CEO RJ Scaringe selling shares. Volume topped 14 million.
17 November 2025
··
Tesla (TSLA) News Today: China Supply Chain Shake-Up, Thiel Trims Stake, AI5 Delay and Divided Wall Street – 17 November 2025

Tesla (TSLA) News Today: China Supply Chain Shake-Up, Thiel Trims Stake, AI5 Delay and Divided Wall Street – 17 November 2025

Tesla shares rose about 2.5% to $414.46 on November 17 after Elon Musk ordered U.S. suppliers to phase out China-made parts within two years. Peter Thiel cut his Tesla stake by over 75% in Q3. Musk said the next-gen AI5 chip is delayed until mid-2027. Wall Street remains split on robotaxi prospects, with price targets ranging from $131 to $509.
17 November 2025
··
Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford shares have surged about 32–37% in 2025, outpacing the S&P 500 and trading near a 52-week high around $13.20. Wall Street cites Ford’s shift away from costly EV projects toward profitable trucks and hybrids, despite ongoing multi-billion-dollar EV losses. Analyst targets average $11.73, with most maintaining a “Hold” rating. The stock’s dividend yield remains near 4.5%.
17 November 2025
···
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor Technologies shares traded at $8.03 on November 17, down 1% after recent highs above $10. The company’s controversial warrant dividend, set for distribution on November 21, targets short sellers and has fueled volatility. Morgan Stanley maintained a Hold rating, while quants noted large hedge fund flows. Opendoor stock remains up several hundred percent year-to-date.
17 November 2025
··
Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings secured an $8.2 million contract to deploy counter-drone systems at a major European airport and closed its $225 million acquisition of Israel-based Sentrycs. The company reported record Q3 revenue of $10.1 million, up more than sixfold year-over-year. ONDS shares traded around $7.00 midday, down 2.5% after recent gains. Analyst price targets rose, with Oppenheimer upgrading the stock to “outperform.”
17 November 2025
··
Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat shares traded near $1.08 Monday after law firm Bleichmar Fonti & Auld LLP announced a new securities-fraud investigation into the company. The probe centers on whether Beyond Meat misled investors about asset values and impairment charges. Short interest has dropped to 13.2%, its lowest since early 2021. The stock remains down about 70% for the year.
17 November 2025
·
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical reported 20–30-point gains in quality-of-life scores at three months in a subgroup analysis from its PoC 1 study for severe pancreatic cancer pain. Even Stage 4 patients saw durable symptom and function improvements after nerve ablation. AMIX shares nearly doubled intraday on heavy volume, ranking among Nasdaq’s top gainers. The company remains pre-revenue and highly volatile.
17 November 2025
··
Michael Saylor’s Strategy Bets $835M on the Bitcoin Dip as Crypto Market Slides Below $95K

Michael Saylor’s Strategy Bets $835M on the Bitcoin Dip as Crypto Market Slides Below $95K

Strategy Inc. bought 8,178 Bitcoin for $835.6 million last week, its largest purchase since July, SEC filings show. The company now holds 649,870 BTC, worth about $62 billion at current prices. Purchases were funded mainly through euro and U.S. preferred share offerings after a sharp drop in Strategy’s common stock. Bitcoin is down roughly 25% from its October high.
17 November 2025
··
MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) surged as much as 40% in pre-market trading on November 17, 2025, reaching $0.62 after closing at $0.45 on Friday. The spike came amid heavy volume and no new company news, as traders responded to recent volatility, a late Q3 filing, and ongoing Nasdaq delisting risk. Market cap remains below $1 million, with the company facing a $1.56 billion net loss in 2024 and a $1.2 billion debt restructuring.
17 November 2025
··
Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab’s B-share jumped 5–6% to SEK 555 on Monday, nearing a 52-week high after the company announced a €3.1bn contract to supply 17 Gripen E/F fighter jets to Colombia. Year-to-date, the stock is up over 120%. Analysts flagged strong order momentum but warned the valuation looks stretched. Saab’s order backlog reached SEK 187bn at 2024 year-end, up from SEK 153bn a year earlier.
17 November 2025
····
Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium shares surged over 30% in premarket U.S. trading Monday, hitting as high as $8.20 on volume exceeding 12 million shares. The rally follows strong Q3 2025 results and a bullish lithium demand forecast from China’s Ganfeng Lithium. Sigma closed Friday at $6.06, up 2.7% on heavy volume. Lithium futures in Guangzhou jumped 9% after Ganfeng projected 30% demand growth in 2026.
17 November 2025
···
Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition, a new $179.99 mobile controller officially licensed for Xbox, is now available through Backbone, Microsoft, Amazon, and Best Buy. The device features full-size ALPS thumbsticks, Hall Effect triggers, two rear paddles, and supports both wired and wireless play across phones, PCs, TVs, and VR headsets. Early reviews highlight its premium build and deep Xbox Cloud Gaming integration.
17 November 2025
·
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy shares rose 4.8% to $0.81 Monday after Canaccord Genuity raised its price target to $2.25 and reiterated a Buy rating, citing a stronger balance sheet. The move followed Q3 results showing a narrower loss of –$0.20 per share versus expectations for –$0.71, with revenue up 26% to $16 million and gross margin expanding to 29.7%.
17 November 2025
··
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
1 … 1,772 1,773 1,774 1,775 1,776 … 2,108

Stock Market Today

  • Miyazaki Bank’s New Stock Option Plan Signals Shift in Governance Strategy
    June 25, 2026, 5:21 PM EDT. Miyazaki Bank (TSE:8393) approved a stock compensation-type stock option plan on June 25, 2026, aiming to better align management and employee incentives with long-term goals. The regional Japanese lender, known for strong recent returns but low return on equity and an unstable dividend history, may see modest changes in risk profile as incentives could now emphasize share price growth over balance sheet conservatism. Key near-term catalysts include an enhanced dividend policy, a 5-for-1 share split, and new leadership adjustment. While the stock is up, it appears overextended by 38%, prompting investors to reassess its fair value. This governance move forms part of broader efforts to strengthen shareholder alignment but is unlikely to materially impact finances short term.

Latest News

Coeur Mining (CDE) gains as buyback impact tops S&P MidCap 400 move

Coeur Mining (CDE) gains as buyback impact tops S&P MidCap 400 move

25 June 2026
Coeur Mining surged 3.4% to $15.99 after joining the S&P MidCap 400 and revealing $680.3 million left in its buyback program—enough to offset about 11% of shares issued for its New Gold acquisition—while boosting its 2026 exploration budget midpoint by 82% to $158 million.
Nano-X Imaging (NASDAQ:NNOX) drops 45% on cash warning, pulls guidance

Nano-X Imaging (NASDAQ:NNOX) drops 45% on cash warning, pulls guidance

25 June 2026
Nano-X Imaging plunged 44.61% to $0.8697 after withdrawing its 2026 revenue target and warning current cash is insufficient to fund operations for at least one year, with Q1 imaging-system and OEM revenue at just $167,000 and net cash estimated at $27 million—less than two quarters at the Q1 burn rate.
Go toTop